Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Immunomedics to Report Fourth Quarter and Fiscal Year 2018 Results and Host Conference Call and Webcast on August 23, 2018

2018-08-16 globenewswire
MORRIS PLAINS, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Thursday, August 23, 2018 at 5:00 p.m. Eastern Time to discuss fourth quarter and fiscal year 2018 financial results and provide a corporate update.
IMMU

4
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

2018-08-08 globenewswire
Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization
IMMU URGN SCMP

23
Forensic Stock Selections For August - First Year Portfolio +96.80%

2018-08-01 seekingalpha - 3
The one year performance of the 2017 Negative Forensic July portfolio ends up +96.80% to lead the pack of the Negative Forensic Portfolios.
LBTY ONCE OMER LBTYK IMMU LILAB PCYO IMGN INVA ACY FRD XOMA NTNX YGYI ACIU JBT LBTYB RTNB LBTYA COE DSKE VRAY CHKE RCM LILAK LILA

1
Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions

2018-07-30 globenewswire
Clinical Collaboration with Yale University to Evaluate Sacituzumab Govitecan in Two Phase 2 Studies in Endometrial and Cervical Cancers
IMMU

63
10 Strong Buy Stocks From the Best Analysts on Wall Street

2018-07-26 investorplace - 2
Now more than ever, it makes sense to listen to analysts with a proven track record of success. Anyone can claim to be a market expert. Anyone can have an opinion. But that opinion becomes a lot more meaningful when the figures show that this person tends to be right.
LOW DB MCHP SAGE WFM BABA AMZN IMMU MU GPOR NTR MS UNH

100
Biotech Stocks Are Tariff-Safe And Building Momentum

2018-07-23 seekingalpha - 1
The Nasdaq Biotechnology Index is poised to make a 52-week high and most likely an all-time high shortly thereafter.
VRTX ECYT LOXO AAV VSTM VKTX ZGNX ENL FIXX LGNDZ RGNX IMMU BIIB CELG LGNYZ HRTX MS INCY NBIX ARWR RARE SRPT ICPT SUPN VKTXW XLRN FGEN LGNZZ LGND NVS LGNXZ PFE ENDP

4
Immunomedics Announces Clinical Collaboration With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers

2018-07-23 globenewswire
MORRIS PLAINS, N.J., July 23, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced a clinical collaboration with AstraZeneca (NYSE:AZN) and its global biologics research and development arm, MedImmune, to evaluate the safety and efficacy of the combination of Imfinzi® (durvalumab), a human monoclonal antibody directed against PD-L1, and Immunomedics’ lead antibody-drug conjugate (ADC) product candidate, sacituzumab govitecan, as a frontline treatment of patients with triple-negative breast cancer (TNBC) and urothelial cancer (UC).
IMMU AZN

83
Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive

2018-07-20 seekingalpha - 1
Discussion: Catalyst Biosciences (CBIO) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptacog alfa (activated) in patients with hemophilia A or B with inhibitors. One administered patient showed significant improvement in prevention of bleeding in the first 96 days. Two other patients are yet to complete the first 50 days of dosing to determine any significant improvement.
MBRX ADAP ENZ AZN KPTI OVID CTIC CTI LLY CLRBZ SNY CLRBW CBIO IMMU JNJ NVS CLRB PFE ATOS

1
IMMU / Immunomedics, Inc. 8-K (Current Report)

2018-07-18 sec.gov
UNITED STATES<
IMMU

3
FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

2018-07-18 globenewswire - 2
MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease.
IMMU

1
IMMU / Immunomedics, Inc. 8-K (Current Report)

2018-07-12 sec.gov
UNITED STATES
IMMU

30
Your Daily Pharma Scoop: IPO Review - Aptinyx Surges, Kezar Progresses, Neon Slumps

2018-07-11 seekingalpha - 2
Aptinyx (APTX) priced its IPO at $16.00. 6.4M common stock shares were offered. Additional 959,999 shares were on underwriters over-allotment. Gross proceeds initially expected was ~102.4M, but reached $117.8M by the time of closing. The shares opened at $17.40 on June 21. The IPO closed on June 25.
GLENMARK APTX ALPMF AUPH DEPO LLY GSK GLKQY CADILAHC CDLYY 4503 MYL 532321 ALPMY AUP NTGN IMMU BMS 532296 JNJ NVS KZR PFE

27
What Does Breakthrough Therapy Designation Really Mean For My Company?

2018-06-23 seekingalpha - 1
Breakthrough Therapy designation is one of the sexier pre-approval stamps that the FDA can place on a drug.
IMMU

33
IMMU / Immunomedics, Inc. 8-K (Current Report)

2018-06-22 sec.gov - 7
UNITED STATES
IMMU

321
A Short Case For A Longer Term!

2018-06-20 seekingalpha - 10
Most investors should favor a longer-term time frame as the markets again record new highs after recovering from the first quarter pullback.
CRC ADAP ECYT LOXO NBIX ARWR SRPT TRXC CHGG SUPN RGNX ARNA TWLO IMMU NDAQ MRTX HEAR TTD

IMMU : Immunomedics Stock Analysis and Research Report

2017-11-11 - Asif

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The company's advanced proprietary technologies allow it to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of six clinical-stage product candidates. The company believe that each of its antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with chemotherapeutics, therapeutic radioisotopes (radiolabeled), cytokines or other toxins to create unique and potentially more effective treatment options. The attachment of various compounds to antibodies is intended to allow the delivery of these therapeutic agents to tumor sites with better specificity than conventional chemothe...

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 452907108